Windsor's Shelter Health granted provincial funding
'We've seen real success stories,' said Nicole Sbrocca, CEO of the Canadian Mental Health Association (CMHA) Windsor-Essex.
'We're already seeing both impressive results in terms of the data but also lived experience from those that are frequenting these clinics and these services.'
The Windsor Shelter Health Association was formed in 2021 to deliver healthcare to those experiencing homelessness. The proof-of-concept model received in-kind support from Windsor Regional, CMHA, and the City of Windsor.
The provincial government came on board last year providing close to $3.9 million in funding through 2026.
'The additional funding means sustainability,' said Shelter Health Medical Director, Jennifer Bondy.
The investment follows the government's recent approval of a Homeless Shelter Alternate Payment Plan (HSAPP) agreement for local physicians.
The group of Windsor physicians is one of four in Ontario receiving the designation and funding.
'This funding is the starting funding, and I have strong feeling we'll see each other again on this in the future,' noted Windsor-Tecumseh MPP Andrew Dowie.
The funding allows for 11 physicians, eight general practitioners, and three specialists to continue delivering care to each of the five key locations:
The Salvation Army Men's Emergency Shelter
The Homelessness and Housing Help Hub (H4)
The Welcome Centre Shelter for Women and Families
The Downtown Mission of Windsor
Journey Home Hospice
Various Housing with Supports sites
Bondy said they are seeing more patients, who can walk in with no appointment.
'When we build trust then we can encourage people to continue to come in, and that is going to lead to improved outcomes, more preventative care, and so a lot less catch up afterwards, which is good for the healthcare system in general because it means then we're spending less money downstream then we would be otherwise,' said Bondy.
The initial stream of government funding has helped physicians provide over 5,000 visits across all shelters. They see, on average, about 200 unique patients a month.
'We've seen improvement in medication adherence and better follow up on both chronic issues and acute health issues,' Sbrocca said.
Officials have seen a reduction in emergency department use for issues now addressed at shelter sites instead.
'There's a lot of good work going on across the province, and I think it's important to lean on what we know works and continue building in that way,' said Bondy, who would like to identify more community partnerships and find out what other sites can be served so the group can help.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Globe and Mail
2 hours ago
- Globe and Mail
Canada is hosting the world's biggest dementia conference for the first time in a decade. What's changed since then?
This week, researchers from around the globe are descending upon downtown Toronto to attend the Alzheimer's Association International Conference, the world's biggest and most influential meeting for dementia research. The gathering is a chance for the international dementia community to discuss the latest research in the field; it's also where significant breakthroughs are often unveiled. At a related event on Saturday, the Canadian Institutes of Health Research (CIHR) – Canada's health research funding agency – announced $44.8-million in new funding for dementia and aging-related research initiatives, including the creation of 16 teams that will study everything from Alzheimer's biomarkers to dementia in Indigenous populations. To set the stage for this year's conference, The Globe and Mail checked in with Jane Rylett, a professor at Western University and scientific director at the CIHR Institute of Aging, which hosted Saturday's event. The last time this global conference was held in Canada was in 2016, nearly a decade ago. How has the dementia research landscape changed since then? This is a really important inflection point. There is a new class of drugs, the antibody therapy, that came into the market within the last three or four years; they probably will be approved in Canada in the coming years. But while there's huge hope around it . . . right now, there's a lot of debate around if they're really beneficial. For certain people, they don't work at all; other people have negative side effects by creating inflammation in the brain. And the benefit-to-risk ratio is not great. So I think at this year's conference, it's going to be really important to hear about new findings with that. Something that's really gained momentum over the last few years is stepping back from the pharmacological approach to treatment and saying, 'What else can we do that will reduce the risk of developing dementia?' Health system urged to brace for major shift in dementia demographics The other thing that's changed is there's always been an 'amyloid hypothesis' of Alzheimer's disease, based on these toxic peptides that get made in the brain and clearly have a role in brain health and development of dementia. But during these nine years, there's been a much greater move towards understanding the role of those and recognizing that while they're still important, they're not the whole story. Now there's more openness to looking at other hypotheses about how brain health can be impacted during the life course and can lead to dementia. How should people feel about this present moment? Thinking back to 2012, the United States' health department set an ambitious goal to prevent and effectively treat Alzheimer's disease by 2025. But here we are today and that goal is far from met. When people or groups make those kinds of statements, it doesn't necessarily mesh with the complication of the thing. And then what happens is people see [the missed deadline] and think, well, it didn't happen. That's always the danger of doing something like that. The brain is a complex thing, it really is. The problem with something like Alzheimer's disease is it's so multi-faceted and it's a spectrum. There's so many areas of the brain that are impacted and the clinical presentation can look similar for people but what's happening in their brain, and where the degeneration is initiated, can be quite different. There's no one pill that you're going to have that's going to be able to change the course or alleviate the symptoms. So was it realistic to say in 2012 that this could be cured by 2025? Probably not. But it stimulated a lot of activity. We understand much more about the underlying pathology and the pathogenesis of the disease. And stepping back was an important thing, saying what can we do that is not a pharmaceutical or a pill? What are the life, behavioural and other things that we can do? Canada has a chance to change the Alzheimer's experience - let's not squander it There's been a lot of focus on the funding cuts in the U.S. that are under way right now, including to the National Institutes of Health (NIH). How has that affected things? is it looming over the conference this year? Yes. A number of Canadian researchers also have been funded by NIH, either in their own right or as subcontracts on larger studies within the U.S., and for the most part, that has been ended, which is very problematic. So we have a number of very good Canadian researchers in all fields that have lost substantial funding, and we don't have the resources in Canada to replace that. One of the big question marks is the impact it's going to have on the number of Americans that are going to be able to attend the conference. And I don't know the answer to that yet. Let's talk about Canadian researchers. What role are they playing within the broader effort? Canadian researchers are leaders internationally in these fields of study. There's really significant work being done by Canadians in the biomarkers area, so the diagnostic area. We have a lot of expertise around how to develop and promote new methods for supporting caregivers and persons with dementia. Alzheimer's trial brings at-risk patients hope for the future, but new doubts in the present We've got outstanding Indigenous cognitive health researchers that are developing new culturally safe and appropriate diagnostic and caregiving methods. And we do have some very good work going on around pathogenesis, looking at changes in the brain during aging and how that may lead to loss of cognition. That's important because you really need to understand where those earliest changes come from. Those are the targets where you need to develop drugs and therapies. This interview has been edited and condensed.
CTV News
2 hours ago
- CTV News
Drug warning issued in North Bay area
Police in North Bay are issuing a high-priority safety alert after a recent probe of an overdose uncovered two extremely dangerous drugs. Eric Taschner has more.
CTV News
2 hours ago
- CTV News
W.E. Care for Kids makes generous donation to Windsor hospital
W.E. Care for Kids donated $127,935.00 to Windsor Regional Hospital on July 22, 2025. (Source: W.E. Care for Kids) W.E. Care for Kids has donated $127,935.00 to Windsor Regional Hospital to support paediatric care for kids and their families. According to the organization, these funds will be used to purchase two Glidescope Core Intubation Systems for the paediatric operating room, along with vital equipment needed in the NICU, Family Birthing Unit and paediatric floor. 'This donation is a reflection of our ongoing mission to ensure children in Windsor-Essex receive the care they need right here at home,' said Viki Grado, executive director of W.E. Care for Kids. 'Keeping kids close to their families during medical treatment is not just about convenience – it's about giving every child the chance to heal and the best environment possible surrounded by the people who love them most.' To date, W.E. Care for Kids has raised over $10 million to improve health care services across Windsor Essex.
